

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC. and MYLAN LABORATORIES  
LIMITED,  
Petitioner,

v.

UCB PHARMA GMBH,  
Patent Owner.

---

Case No. IPR2016-00510<sup>1</sup>  
Patent No. 6,858,650 B1

---

**PATENT OWNER'S UPDATED MANDATORY  
NOTICE INFORMATION  
UNDER 37 C.F.R. § 42.8**

---

<sup>1</sup> Petitioners Alembic Pharmaceuticals Limited from IPR2016-01596, Torrent Pharmaceuticals Limited from IPR2016-01636, and Amerigen Pharmaceuticals Limited from IPR2016-01665 have been joined as Petitioners to this proceeding.

Patent Owner UCB Pharma GmbH hereby submits Updated Mandatory Notice Information pursuant to 37 C.F.R. § 42.8 to identify any other judicial or administrative matter that would affect, or be affected by, a decision in the proceeding. Patent Owner identifies that the District Court of Delaware has conducted a trial in the related matter of *Pfizer, Inc. and UCB Pharma GmbH v. Mylan Pharmaceuticals Inc.*, No. 1:15-cv-00079-GMS (D. Del.). At the conclusion of the 3-day bench trial, which commenced on January 23, 2017, Judge Sleet entered a general verdict in favor of Plaintiffs and found the asserted claims of U.S. Patent Nos. 6,858,650; 7,384,980; 7,855,230; 7,985,772; and 8,338,478 (collectively, the “asserted patents”) not obvious.

Additionally, UCB Pharma GmbH and Pfizer Inc., the exclusive licensee of the asserted patents, have filed suit against Torrent Pharmaceuticals Limited and Torrent Pharma Incorporated for infringement of the asserted patents in the following action: *Pfizer, Inc. and UCB Pharma GmbH v. Torrent Pharmaceuticals Limited et al.*, No. 1:17-cv-00112-GMS (D. Del.).

WHITE & CASE LLP

/s/ Jeffrey J. Oelke

Jeffrey J. Oelke, Reg. No. 37,409

[joelke@whitecase.com](mailto:joelke@whitecase.com)

James S. Trainor, Jr., Reg. No. 52,297

[jtrainor@whitecase.com](mailto:jtrainor@whitecase.com)

Robert Counihan, Reg. No. 61,382

[rcounihan@whitecase.com](mailto:rcounihan@whitecase.com)

White & Case LLP

1155 Avenue of the Americas

New York, NY 10036

(212) 819-8200

*Attorneys for UCB Pharma GmbH*

Date: February 16, 2017

## CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing Patent Owner's Updated Mandatory Notice Information Under 37 C.F.R. § 42.8 was served on February 16, 2017, by filing this document through the Patent Trial and Appeal Board End to End System as well as delivering a copy via electronic mail upon the following attorneys of record for the Petitioner:

Mitchell G. Stockwell, Reg. No. 39,389  
[mstockwell@kilpatricktownsend.com](mailto:mstockwell@kilpatricktownsend.com)  
D. Clay Holloway, Reg. No. 58,011  
[cholloway@kilpatricktownsend.com](mailto:cholloway@kilpatricktownsend.com)  
Alyson L. Wooten, Reg. No. 58,045  
[awooten@kilpatricktownsend.com](mailto:awooten@kilpatricktownsend.com)  
Kilpatrick Townsend & Stockton LLP  
1100 Peachtree Street, NE Suite 2800  
Atlanta, Georgia 30309  
(404) 815-6500

Bill Hare  
[bill@miplaw.com](mailto:bill@miplaw.com)  
Gabriella Materassi  
[materassi@miplaw.com](mailto:materassi@miplaw.com)  
Renita Rathinam  
[rathinam@miplaw.com](mailto:rathinam@miplaw.com)  
McNeely, Hare & War LLP  
5335 Wisconsin Ave, NW, Suite 440  
Washington, DC 20015  
(202) 640-1801

Lawrence M. Sung  
[lsung@wileyrein.com](mailto:lsung@wileyrein.com)  
A. Neal Seth  
[nseth@wileyrein.com](mailto:nseth@wileyrein.com)  
Wiley Rein LLP  
1776 K Street NW  
Washington, DC 20006  
(202) 719-7000

Manish K. Mehta  
[mmehta@sheppardmullin.com](mailto:mmehta@sheppardmullin.com)  
Laura M. Burson  
[lburson@sheppardmullin.com](mailto:lburson@sheppardmullin.com)  
Sheppard, Mullin, Richter & Hampton LLP  
Three First National Plaza  
70 West Madison Street, 48th Floor  
Chicago, IL 60602  
(312) 499-6300

Respectfully submitted

/s/ Jeffrey J. Oelke

Jeffrey J. Oelke  
Reg. No. 37,409  
Phone: (212) 819-8936

Date: February 16, 2017